Skip to main content

Table 2 Echocardiography parameters

From: A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study

 

Empagliflozin

Sitagliptin

p value

LVEF (%)

 Baseline

73.4 ± 5.6

74.2 ± 4.5

0.620

 12 weeks

73.5 ± 4.2

72.6 ± 5.0

0.539

 Change

0.1 ± 4.0

−1.6 ± 3.0

0.138

 Intragroup p value

0.932

0.026*

 

%FS (%)

 Baseline

42.9 ± 4.6

43.5 ± 4.0

0.625

 12 weeks

42.9 ± 3.5

42.1 ± 4.1

0.521

 Change

0.0 ± 3.5

−1.4 ± 2.7

0.147

 Intragroup p value

0.985

0.024*

 

E/e′

 Baseline

10.9 ± 3.6

10.0 ± 2.7

0.397

 12 weeks

10.3 ± 3.2

9.3 ± 1.8

0.188

 Change

−0.5 ± 2.4

−0.8 ± 3.1

0.780

 Intragroup p value

0.310

0.256

 

E/A

 Baseline

0.88 ± 0.25

1.01 ± 0.31

0.132

 12 weeks

0.92 ± 0.23

1.01 ± 0.36

0.307

 Change

0.04 ± 0.17

0.00 ± 0.19

0.500

 Intragroup p value

0.296

0.963

 

Cardiac index (L/min/m2)

 Baseline

3.32 ± 0.75

3.14 ± 0.60

0.408

 12 weeks

3.41 ± 0.60

3.03 ± 0.55

0.036*

 Change

0.09 ± 0.74

−0.12 ± 0.53

0.296

 Intragroup p value

0.566

0.325

 

LV mass (g)

 Baseline

153.6 ± 43.0

161.1 ± 38.2

0.555

 12 weeks

152.1 ± 44.4

155.1 ± 32.5

0.804

 Change

−1.5 ± 15.9

−6.0 ± 19.7

0.424

 Intragroup p value

0.666

0.180

 
  1. Data are presented as the mean ± SD (n = 21 for both groups). p values < 0.05 indicate significant differences. Comparisons were performed by one-sample t-test in each group, and two-sample t-tests between groups. LVEF: left ventricle ejection fraction, FS: fractional shortening, E/e′: ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity, E/A: early filling/atrial filling ratio. *p < 0.05
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840